nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—JUN—liver cancer	0.647	1	CbGaD
Irbesartan—CYP2C8—Sorafenib—liver cancer	0.0267	0.241	CbGbCtD
Irbesartan—CYP1A2—Sorafenib—liver cancer	0.0206	0.187	CbGbCtD
Irbesartan—CYP2C9—Sorafenib—liver cancer	0.0186	0.168	CbGbCtD
Irbesartan—CYP2D6—Sorafenib—liver cancer	0.017	0.154	CbGbCtD
Irbesartan—CYP3A4—Sorafenib—liver cancer	0.0108	0.0978	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—liver cancer	0.0103	0.0933	CbGbCtD
Irbesartan—CYP3A4—Doxorubicin—liver cancer	0.00656	0.0593	CbGbCtD
Irbesartan—Constipation—Sorafenib—liver cancer	0.000262	0.00279	CcSEcCtD
Irbesartan—Pain—Sorafenib—liver cancer	0.000262	0.00279	CcSEcCtD
Irbesartan—Pulmonary oedema—Doxorubicin—liver cancer	0.000261	0.00278	CcSEcCtD
Irbesartan—Gastrointestinal pain—Sorafenib—liver cancer	0.00025	0.00266	CcSEcCtD
Irbesartan—Hot flush—Epirubicin—liver cancer	0.000246	0.00262	CcSEcCtD
Irbesartan—Increased appetite—Epirubicin—liver cancer	0.000245	0.00261	CcSEcCtD
Irbesartan—Diabetes mellitus—Doxorubicin—liver cancer	0.000245	0.00261	CcSEcCtD
Irbesartan—Menopausal symptoms—Epirubicin—liver cancer	0.000244	0.0026	CcSEcCtD
Irbesartan—Hepatic function abnormal—Doxorubicin—liver cancer	0.000244	0.00259	CcSEcCtD
Irbesartan—Urticaria—Sorafenib—liver cancer	0.000243	0.00259	CcSEcCtD
Irbesartan—Photosensitivity—Doxorubicin—liver cancer	0.000242	0.00258	CcSEcCtD
Irbesartan—Abdominal pain—Sorafenib—liver cancer	0.000242	0.00258	CcSEcCtD
Irbesartan—Body temperature increased—Sorafenib—liver cancer	0.000242	0.00258	CcSEcCtD
Irbesartan—Renal impairment—Epirubicin—liver cancer	0.000242	0.00257	CcSEcCtD
Irbesartan—Cerebrovascular accident—Epirubicin—liver cancer	0.000235	0.0025	CcSEcCtD
Irbesartan—Hyponatraemia—Epirubicin—liver cancer	0.000231	0.00246	CcSEcCtD
Irbesartan—Hot flush—Doxorubicin—liver cancer	0.000228	0.00242	CcSEcCtD
Irbesartan—Increased appetite—Doxorubicin—liver cancer	0.000227	0.00241	CcSEcCtD
Irbesartan—Affect lability—Epirubicin—liver cancer	0.000226	0.00241	CcSEcCtD
Irbesartan—Menopausal symptoms—Doxorubicin—liver cancer	0.000226	0.0024	CcSEcCtD
Irbesartan—Hypersensitivity—Sorafenib—liver cancer	0.000225	0.0024	CcSEcCtD
Irbesartan—Renal impairment—Doxorubicin—liver cancer	0.000224	0.00238	CcSEcCtD
Irbesartan—Face oedema—Epirubicin—liver cancer	0.000222	0.00237	CcSEcCtD
Irbesartan—Asthenia—Sorafenib—liver cancer	0.00022	0.00234	CcSEcCtD
Irbesartan—Mood swings—Epirubicin—liver cancer	0.000218	0.00232	CcSEcCtD
Irbesartan—Cerebrovascular accident—Doxorubicin—liver cancer	0.000217	0.00231	CcSEcCtD
Irbesartan—Pruritus—Sorafenib—liver cancer	0.000216	0.0023	CcSEcCtD
Irbesartan—Hyponatraemia—Doxorubicin—liver cancer	0.000214	0.00228	CcSEcCtD
Irbesartan—Liver function test abnormal—Epirubicin—liver cancer	0.000212	0.00226	CcSEcCtD
Irbesartan—Orthostatic hypotension—Epirubicin—liver cancer	0.00021	0.00224	CcSEcCtD
Irbesartan—Abdominal pain upper—Epirubicin—liver cancer	0.00021	0.00224	CcSEcCtD
Irbesartan—Affect lability—Doxorubicin—liver cancer	0.00021	0.00223	CcSEcCtD
Irbesartan—Hypokalaemia—Epirubicin—liver cancer	0.000209	0.00223	CcSEcCtD
Irbesartan—Diarrhoea—Sorafenib—liver cancer	0.000209	0.00223	CcSEcCtD
Irbesartan—Breast disorder—Epirubicin—liver cancer	0.000208	0.00221	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000207	0.00221	CcSEcCtD
Irbesartan—Nasopharyngitis—Epirubicin—liver cancer	0.000206	0.00219	CcSEcCtD
Irbesartan—Face oedema—Doxorubicin—liver cancer	0.000206	0.00219	CcSEcCtD
Irbesartan—Muscular weakness—Epirubicin—liver cancer	0.000203	0.00216	CcSEcCtD
Irbesartan—Dizziness—Sorafenib—liver cancer	0.000202	0.00215	CcSEcCtD
Irbesartan—Mood swings—Doxorubicin—liver cancer	0.000202	0.00215	CcSEcCtD
Irbesartan—Abdominal distension—Epirubicin—liver cancer	0.0002	0.00213	CcSEcCtD
Irbesartan—Influenza—Epirubicin—liver cancer	0.000199	0.00212	CcSEcCtD
Irbesartan—Asthma—Epirubicin—liver cancer	0.000199	0.00212	CcSEcCtD
Irbesartan—Dysphagia—Epirubicin—liver cancer	0.000199	0.00212	CcSEcCtD
Irbesartan—Liver function test abnormal—Doxorubicin—liver cancer	0.000197	0.00209	CcSEcCtD
Irbesartan—Pancreatitis—Epirubicin—liver cancer	0.000195	0.00208	CcSEcCtD
Irbesartan—Vomiting—Sorafenib—liver cancer	0.000195	0.00207	CcSEcCtD
Irbesartan—Orthostatic hypotension—Doxorubicin—liver cancer	0.000194	0.00207	CcSEcCtD
Irbesartan—Abdominal pain upper—Doxorubicin—liver cancer	0.000194	0.00207	CcSEcCtD
Irbesartan—Hypokalaemia—Doxorubicin—liver cancer	0.000194	0.00206	CcSEcCtD
Irbesartan—Angina pectoris—Epirubicin—liver cancer	0.000194	0.00206	CcSEcCtD
Irbesartan—Rash—Sorafenib—liver cancer	0.000193	0.00205	CcSEcCtD
Irbesartan—Dermatitis—Sorafenib—liver cancer	0.000193	0.00205	CcSEcCtD
Irbesartan—Breast disorder—Doxorubicin—liver cancer	0.000192	0.00205	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000192	0.00204	CcSEcCtD
Irbesartan—Headache—Sorafenib—liver cancer	0.000192	0.00204	CcSEcCtD
Irbesartan—Nasopharyngitis—Doxorubicin—liver cancer	0.00019	0.00203	CcSEcCtD
Irbesartan—Muscular weakness—Doxorubicin—liver cancer	0.000188	0.002	CcSEcCtD
Irbesartan—Neutropenia—Epirubicin—liver cancer	0.000186	0.00198	CcSEcCtD
Irbesartan—Abdominal distension—Doxorubicin—liver cancer	0.000185	0.00197	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Epirubicin—liver cancer	0.000185	0.00197	CcSEcCtD
Irbesartan—Asthma—Doxorubicin—liver cancer	0.000184	0.00196	CcSEcCtD
Irbesartan—Influenza—Doxorubicin—liver cancer	0.000184	0.00196	CcSEcCtD
Irbesartan—Dysphagia—Doxorubicin—liver cancer	0.000184	0.00196	CcSEcCtD
Irbesartan—Nausea—Sorafenib—liver cancer	0.000182	0.00194	CcSEcCtD
Irbesartan—Photosensitivity reaction—Epirubicin—liver cancer	0.000182	0.00193	CcSEcCtD
Irbesartan—Weight increased—Epirubicin—liver cancer	0.000181	0.00193	CcSEcCtD
Irbesartan—Pancreatitis—Doxorubicin—liver cancer	0.00018	0.00192	CcSEcCtD
Irbesartan—Hyperglycaemia—Epirubicin—liver cancer	0.000179	0.00191	CcSEcCtD
Irbesartan—Angina pectoris—Doxorubicin—liver cancer	0.000179	0.00191	CcSEcCtD
Irbesartan—Pneumonia—Epirubicin—liver cancer	0.000178	0.0019	CcSEcCtD
Irbesartan—Renal failure—Epirubicin—liver cancer	0.000174	0.00186	CcSEcCtD
Irbesartan—Jaundice—Epirubicin—liver cancer	0.000173	0.00184	CcSEcCtD
Irbesartan—Urinary tract infection—Epirubicin—liver cancer	0.000172	0.00184	CcSEcCtD
Irbesartan—Conjunctivitis—Epirubicin—liver cancer	0.000172	0.00184	CcSEcCtD
Irbesartan—Neutropenia—Doxorubicin—liver cancer	0.000172	0.00183	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000171	0.00182	CcSEcCtD
Irbesartan—Photosensitivity reaction—Doxorubicin—liver cancer	0.000168	0.00179	CcSEcCtD
Irbesartan—Hepatobiliary disease—Epirubicin—liver cancer	0.000168	0.00179	CcSEcCtD
Irbesartan—Weight increased—Doxorubicin—liver cancer	0.000167	0.00178	CcSEcCtD
Irbesartan—Epistaxis—Epirubicin—liver cancer	0.000167	0.00178	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—liver cancer	0.000166	0.00177	CcSEcCtD
Irbesartan—Agranulocytosis—Epirubicin—liver cancer	0.000165	0.00176	CcSEcCtD
Irbesartan—Pneumonia—Doxorubicin—liver cancer	0.000165	0.00176	CcSEcCtD
Irbesartan—Bradycardia—Epirubicin—liver cancer	0.000162	0.00173	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—liver cancer	0.000161	0.00172	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—liver cancer	0.00016	0.0017	CcSEcCtD
Irbesartan—Rhinitis—Epirubicin—liver cancer	0.00016	0.0017	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—liver cancer	0.000159	0.0017	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—liver cancer	0.000159	0.0017	CcSEcCtD
Irbesartan—Hepatitis—Epirubicin—liver cancer	0.000159	0.00169	CcSEcCtD
Irbesartan—Hypoaesthesia—Epirubicin—liver cancer	0.000158	0.00169	CcSEcCtD
Irbesartan—Pharyngitis—Epirubicin—liver cancer	0.000158	0.00168	CcSEcCtD
Irbesartan—Urinary tract disorder—Epirubicin—liver cancer	0.000157	0.00167	CcSEcCtD
Irbesartan—Oedema peripheral—Epirubicin—liver cancer	0.000157	0.00167	CcSEcCtD
Irbesartan—Connective tissue disorder—Epirubicin—liver cancer	0.000156	0.00167	CcSEcCtD
Irbesartan—Urethral disorder—Epirubicin—liver cancer	0.000156	0.00166	CcSEcCtD
Irbesartan—Hepatobiliary disease—Doxorubicin—liver cancer	0.000155	0.00165	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—liver cancer	0.000155	0.00165	CcSEcCtD
Irbesartan—Visual impairment—Epirubicin—liver cancer	0.000153	0.00163	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—liver cancer	0.000153	0.00163	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—liver cancer	0.00015	0.0016	CcSEcCtD
Irbesartan—Tinnitus—Epirubicin—liver cancer	0.000148	0.00158	CcSEcCtD
Irbesartan—Flushing—Epirubicin—liver cancer	0.000148	0.00157	CcSEcCtD
Irbesartan—Cardiac disorder—Epirubicin—liver cancer	0.000148	0.00157	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—liver cancer	0.000148	0.00157	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—liver cancer	0.000147	0.00157	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—liver cancer	0.000147	0.00156	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—liver cancer	0.000146	0.00156	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—liver cancer	0.000145	0.00155	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—liver cancer	0.000145	0.00154	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—liver cancer	0.000145	0.00154	CcSEcCtD
Irbesartan—Angiopathy—Epirubicin—liver cancer	0.000144	0.00154	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—liver cancer	0.000144	0.00154	CcSEcCtD
Irbesartan—Immune system disorder—Epirubicin—liver cancer	0.000144	0.00153	CcSEcCtD
Irbesartan—Mediastinal disorder—Epirubicin—liver cancer	0.000143	0.00153	CcSEcCtD
Irbesartan—Chills—Epirubicin—liver cancer	0.000143	0.00152	CcSEcCtD
Irbesartan—Arrhythmia—Epirubicin—liver cancer	0.000142	0.00151	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—liver cancer	0.000142	0.00151	CcSEcCtD
Irbesartan—Malnutrition—Epirubicin—liver cancer	0.000139	0.00148	CcSEcCtD
Irbesartan—Erythema—Epirubicin—liver cancer	0.000139	0.00148	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—liver cancer	0.000137	0.00146	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—liver cancer	0.000137	0.00146	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—liver cancer	0.000137	0.00146	CcSEcCtD
Irbesartan—Flatulence—Epirubicin—liver cancer	0.000137	0.00145	CcSEcCtD
Irbesartan—Tension—Epirubicin—liver cancer	0.000136	0.00145	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—liver cancer	0.000136	0.00144	CcSEcCtD
Irbesartan—Nervousness—Epirubicin—liver cancer	0.000135	0.00143	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—liver cancer	0.000134	0.00142	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—liver cancer	0.000133	0.00142	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—liver cancer	0.000133	0.00142	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—liver cancer	0.000133	0.00141	CcSEcCtD
Irbesartan—Chills—Doxorubicin—liver cancer	0.000132	0.00141	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—liver cancer	0.000132	0.0014	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—liver cancer	0.000131	0.00139	CcSEcCtD
Irbesartan—Ill-defined disorder—Epirubicin—liver cancer	0.000129	0.00137	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—liver cancer	0.000128	0.00137	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—liver cancer	0.000128	0.00137	CcSEcCtD
Irbesartan—Anaemia—Epirubicin—liver cancer	0.000128	0.00136	CcSEcCtD
Irbesartan—Agitation—Epirubicin—liver cancer	0.000127	0.00136	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—liver cancer	0.000126	0.00135	CcSEcCtD
Irbesartan—Tension—Doxorubicin—liver cancer	0.000126	0.00134	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—liver cancer	0.000126	0.00134	CcSEcCtD
Irbesartan—Malaise—Epirubicin—liver cancer	0.000125	0.00133	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—liver cancer	0.000125	0.00133	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—liver cancer	0.000124	0.00133	CcSEcCtD
Irbesartan—Syncope—Epirubicin—liver cancer	0.000124	0.00132	CcSEcCtD
Irbesartan—Leukopenia—Epirubicin—liver cancer	0.000124	0.00132	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—liver cancer	0.000123	0.00131	CcSEcCtD
Irbesartan—Loss of consciousness—Epirubicin—liver cancer	0.000122	0.0013	CcSEcCtD
Irbesartan—Cough—Epirubicin—liver cancer	0.000121	0.00129	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—liver cancer	0.000121	0.00129	CcSEcCtD
Irbesartan—Hypertension—Epirubicin—liver cancer	0.00012	0.00127	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—liver cancer	0.000119	0.00127	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—liver cancer	0.000118	0.00126	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—liver cancer	0.000118	0.00126	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—liver cancer	0.000118	0.00126	CcSEcCtD
Irbesartan—Chest pain—Epirubicin—liver cancer	0.000118	0.00126	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—liver cancer	0.000118	0.00125	CcSEcCtD
Irbesartan—Anxiety—Epirubicin—liver cancer	0.000118	0.00125	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000117	0.00125	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—liver cancer	0.000117	0.00124	CcSEcCtD
Irbesartan—Malaise—Doxorubicin—liver cancer	0.000116	0.00123	CcSEcCtD
Irbesartan—Dry mouth—Epirubicin—liver cancer	0.000115	0.00123	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—liver cancer	0.000115	0.00123	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—liver cancer	0.000115	0.00122	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—liver cancer	0.000115	0.00122	CcSEcCtD
Irbesartan—Anaphylactic shock—Epirubicin—liver cancer	0.000113	0.0012	CcSEcCtD
Irbesartan—Oedema—Epirubicin—liver cancer	0.000113	0.0012	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—liver cancer	0.000113	0.0012	CcSEcCtD
Irbesartan—Infection—Epirubicin—liver cancer	0.000112	0.0012	CcSEcCtD
Irbesartan—Cough—Doxorubicin—liver cancer	0.000112	0.00119	CcSEcCtD
Irbesartan—Shock—Epirubicin—liver cancer	0.000111	0.00118	CcSEcCtD
Irbesartan—Nervous system disorder—Epirubicin—liver cancer	0.000111	0.00118	CcSEcCtD
Irbesartan—Thrombocytopenia—Epirubicin—liver cancer	0.000111	0.00118	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—liver cancer	0.000111	0.00118	CcSEcCtD
Irbesartan—Tachycardia—Epirubicin—liver cancer	0.00011	0.00118	CcSEcCtD
Irbesartan—Skin disorder—Epirubicin—liver cancer	0.00011	0.00117	CcSEcCtD
Irbesartan—Hyperhidrosis—Epirubicin—liver cancer	0.000109	0.00116	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—liver cancer	0.000109	0.00116	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—liver cancer	0.000109	0.00116	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—liver cancer	0.000109	0.00116	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—liver cancer	0.000109	0.00116	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000108	0.00115	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—liver cancer	0.000108	0.00115	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—liver cancer	0.000108	0.00115	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—liver cancer	0.000107	0.00114	CcSEcCtD
Irbesartan—Hypotension—Epirubicin—liver cancer	0.000106	0.00113	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—liver cancer	0.000105	0.00111	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—liver cancer	0.000105	0.00111	CcSEcCtD
Irbesartan—Infection—Doxorubicin—liver cancer	0.000104	0.00111	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000103	0.0011	CcSEcCtD
Irbesartan—Shock—Doxorubicin—liver cancer	0.000103	0.0011	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—liver cancer	0.000103	0.00109	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—liver cancer	0.000102	0.00109	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—liver cancer	0.000102	0.00109	CcSEcCtD
Irbesartan—Skin disorder—Doxorubicin—liver cancer	0.000102	0.00108	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—liver cancer	0.000102	0.00108	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—liver cancer	0.000101	0.00108	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—liver cancer	0.000101	0.00107	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—liver cancer	0.000101	0.00107	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—liver cancer	9.97e-05	0.00106	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—liver cancer	9.95e-05	0.00106	CcSEcCtD
Irbesartan—Decreased appetite—Epirubicin—liver cancer	9.83e-05	0.00105	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—liver cancer	9.78e-05	0.00104	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—liver cancer	9.76e-05	0.00104	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—liver cancer	9.75e-05	0.00104	CcSEcCtD
Irbesartan—Constipation—Epirubicin—liver cancer	9.67e-05	0.00103	CcSEcCtD
Irbesartan—Pain—Epirubicin—liver cancer	9.67e-05	0.00103	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—liver cancer	9.53e-05	0.00102	CcSEcCtD
Irbesartan—Paraesthesia—Doxorubicin—liver cancer	9.4e-05	0.001	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—liver cancer	9.33e-05	0.000993	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—liver cancer	9.32e-05	0.000992	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—liver cancer	9.3e-05	0.00099	CcSEcCtD
Irbesartan—Gastrointestinal pain—Epirubicin—liver cancer	9.25e-05	0.000985	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—liver cancer	9.21e-05	0.000981	CcSEcCtD
Irbesartan—Decreased appetite—Doxorubicin—liver cancer	9.1e-05	0.000968	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—liver cancer	9.03e-05	0.000962	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—liver cancer	9.02e-05	0.00096	CcSEcCtD
Irbesartan—Urticaria—Epirubicin—liver cancer	8.98e-05	0.000957	CcSEcCtD
Irbesartan—Valsartan—ALB—liver cancer	8.97e-05	0.672	CrCbGaD
Irbesartan—Pain—Doxorubicin—liver cancer	8.95e-05	0.000953	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—liver cancer	8.95e-05	0.000953	CcSEcCtD
Irbesartan—Abdominal pain—Epirubicin—liver cancer	8.94e-05	0.000952	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—liver cancer	8.94e-05	0.000952	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—liver cancer	8.62e-05	0.000918	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—liver cancer	8.56e-05	0.000911	CcSEcCtD
Irbesartan—Hypersensitivity—Epirubicin—liver cancer	8.33e-05	0.000887	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—liver cancer	8.31e-05	0.000885	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—liver cancer	8.27e-05	0.000881	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—liver cancer	8.27e-05	0.000881	CcSEcCtD
Irbesartan—Asthenia—Epirubicin—liver cancer	8.11e-05	0.000864	CcSEcCtD
Irbesartan—Pruritus—Epirubicin—liver cancer	8e-05	0.000852	CcSEcCtD
Irbesartan—Diarrhoea—Epirubicin—liver cancer	7.74e-05	0.000824	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—liver cancer	7.71e-05	0.000821	CcSEcCtD
Irbesartan—Asthenia—Doxorubicin—liver cancer	7.51e-05	0.000799	CcSEcCtD
Irbesartan—Dizziness—Epirubicin—liver cancer	7.48e-05	0.000796	CcSEcCtD
Irbesartan—Pruritus—Doxorubicin—liver cancer	7.4e-05	0.000788	CcSEcCtD
Irbesartan—Vomiting—Epirubicin—liver cancer	7.19e-05	0.000766	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—liver cancer	7.16e-05	0.000762	CcSEcCtD
Irbesartan—Rash—Epirubicin—liver cancer	7.13e-05	0.000759	CcSEcCtD
Irbesartan—Dermatitis—Epirubicin—liver cancer	7.12e-05	0.000758	CcSEcCtD
Irbesartan—Headache—Epirubicin—liver cancer	7.08e-05	0.000754	CcSEcCtD
Irbesartan—Dizziness—Doxorubicin—liver cancer	6.92e-05	0.000737	CcSEcCtD
Irbesartan—Nausea—Epirubicin—liver cancer	6.72e-05	0.000715	CcSEcCtD
Irbesartan—Vomiting—Doxorubicin—liver cancer	6.65e-05	0.000708	CcSEcCtD
Irbesartan—Rash—Doxorubicin—liver cancer	6.6e-05	0.000702	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—liver cancer	6.59e-05	0.000702	CcSEcCtD
Irbesartan—Headache—Doxorubicin—liver cancer	6.55e-05	0.000698	CcSEcCtD
Irbesartan—Nausea—Doxorubicin—liver cancer	6.21e-05	0.000662	CcSEcCtD
Irbesartan—Losartan—ALB—liver cancer	4.38e-05	0.328	CrCbGaD
Irbesartan—EDNRA—Signaling Pathways—CCND1—liver cancer	8.64e-06	5.81e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—liver cancer	8.63e-06	5.8e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—JUN—liver cancer	8.62e-06	5.8e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—PIK3CA—liver cancer	8.61e-06	5.78e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SERPINE1—liver cancer	8.6e-06	5.78e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CTNNB1—liver cancer	8.56e-06	5.75e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALDOB—liver cancer	8.55e-06	5.74e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—liver cancer	8.51e-06	5.72e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	8.5e-06	5.71e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—liver cancer	8.48e-06	5.7e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALDOB—liver cancer	8.47e-06	5.69e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP9—liver cancer	8.39e-06	5.64e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CB—liver cancer	8.39e-06	5.64e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CDKN1A—liver cancer	8.36e-06	5.62e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTM1—liver cancer	8.3e-06	5.58e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDKN1B—liver cancer	8.21e-06	5.52e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK8—liver cancer	8.16e-06	5.48e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CRABP1—liver cancer	8.15e-06	5.48e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—liver cancer	8.14e-06	5.47e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTA4—liver cancer	8.12e-06	5.46e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IL6—liver cancer	8.11e-06	5.45e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CRABP1—liver cancer	8.08e-06	5.43e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2—liver cancer	8.04e-06	5.4e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KDR—liver cancer	8.02e-06	5.39e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK14—liver cancer	7.96e-06	5.35e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	7.94e-06	5.34e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTA2—liver cancer	7.92e-06	5.32e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP1A1—liver cancer	7.87e-06	5.29e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	7.86e-06	5.28e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PIK3CA—liver cancer	7.82e-06	5.25e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ESR1—liver cancer	7.81e-06	5.25e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	7.76e-06	5.22e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CTNNB1—liver cancer	7.76e-06	5.22e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RAF1—liver cancer	7.76e-06	5.21e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PSMA4—liver cancer	7.74e-06	5.2e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PSMD10—liver cancer	7.74e-06	5.2e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—F2—liver cancer	7.72e-06	5.19e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTA1—liver cancer	7.64e-06	5.13e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDKN1A—liver cancer	7.58e-06	5.09e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MTOR—liver cancer	7.57e-06	5.09e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CB—liver cancer	7.57e-06	5.09e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NAT2—liver cancer	7.55e-06	5.08e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—liver cancer	7.53e-06	5.06e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GOT2—liver cancer	7.53e-06	5.06e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—liver cancer	7.48e-06	5.03e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STAT3—liver cancer	7.46e-06	5.01e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK8—liver cancer	7.4e-06	4.97e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CG—liver cancer	7.39e-06	4.96e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—APC—liver cancer	7.39e-06	4.96e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—MTHFR—liver cancer	7.34e-06	4.93e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	7.28e-06	4.89e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	7.26e-06	4.88e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALDOB—liver cancer	7.24e-06	4.87e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—liver cancer	7.23e-06	4.86e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CPT1B—liver cancer	7.23e-06	4.86e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GLUL—liver cancer	7.23e-06	4.86e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARA—liver cancer	7.2e-06	4.84e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HPGDS—liver cancer	7.13e-06	4.79e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1B—liver cancer	7.11e-06	4.78e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP2E1—liver cancer	7.08e-06	4.76e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HPGDS—liver cancer	7.07e-06	4.75e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—liver cancer	7.03e-06	4.73e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	7.02e-06	4.72e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NR1H4—liver cancer	6.97e-06	4.69e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CASP3—liver cancer	6.97e-06	4.68e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—liver cancer	6.96e-06	4.68e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BRAF—liver cancer	6.94e-06	4.67e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—liver cancer	6.93e-06	4.66e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—liver cancer	6.92e-06	4.65e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TGFB1—liver cancer	6.91e-06	4.65e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CRABP1—liver cancer	6.91e-06	4.64e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTA3—liver cancer	6.86e-06	4.61e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	6.85e-06	4.61e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—liver cancer	6.78e-06	4.56e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—JUN—liver cancer	6.77e-06	4.55e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—STAT3—liver cancer	6.76e-06	4.55e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CTNNB1—liver cancer	6.72e-06	4.51e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYCS—liver cancer	6.62e-06	4.45e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—liver cancer	6.58e-06	4.42e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1A—liver cancer	6.56e-06	4.41e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GOT1—liver cancer	6.5e-06	4.37e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GGT1—liver cancer	6.5e-06	4.37e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CD—liver cancer	6.49e-06	4.36e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.47e-06	4.35e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SERPINE1—liver cancer	6.42e-06	4.32e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—liver cancer	6.4e-06	4.3e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK8—liver cancer	6.4e-06	4.3e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.4e-06	4.3e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—liver cancer	6.39e-06	4.29e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PSMA4—liver cancer	6.35e-06	4.27e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PSMD10—liver cancer	6.35e-06	4.27e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	6.32e-06	4.24e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PSMA4—liver cancer	6.3e-06	4.23e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PSMD10—liver cancer	6.3e-06	4.23e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTA4—liver cancer	6.27e-06	4.21e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	6.22e-06	4.18e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GOT2—liver cancer	6.18e-06	4.15e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CG—liver cancer	6.17e-06	4.14e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GOT2—liver cancer	6.13e-06	4.12e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTA2—liver cancer	6.11e-06	4.11e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HPGDS—liver cancer	6.04e-06	4.06e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6e-06	4.03e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARG—liver cancer	5.95e-06	4e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—liver cancer	5.91e-06	3.97e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTA1—liver cancer	5.89e-06	3.96e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—liver cancer	5.88e-06	3.95e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—liver cancer	5.85e-06	3.93e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTP1—liver cancer	5.84e-06	3.92e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NAT2—liver cancer	5.83e-06	3.92e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP2E1—liver cancer	5.81e-06	3.9e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—liver cancer	5.81e-06	3.9e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RAF1—liver cancer	5.8e-06	3.9e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP2E1—liver cancer	5.76e-06	3.87e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HMOX1—liver cancer	5.76e-06	3.87e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—liver cancer	5.69e-06	3.83e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CB—liver cancer	5.66e-06	3.8e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MTOR—liver cancer	5.66e-06	3.8e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALDOB—liver cancer	5.59e-06	3.76e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.58e-06	3.75e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.47e-06	3.67e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—liver cancer	5.44e-06	3.66e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—liver cancer	5.44e-06	3.66e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYCS—liver cancer	5.44e-06	3.65e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFB1—liver cancer	5.43e-06	3.65e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CD—liver cancer	5.42e-06	3.64e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.4e-06	3.63e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYCS—liver cancer	5.39e-06	3.62e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PSMD10—liver cancer	5.38e-06	3.62e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PSMA4—liver cancer	5.38e-06	3.62e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTM1—liver cancer	5.36e-06	3.6e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ALB—liver cancer	5.35e-06	3.6e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—liver cancer	5.34e-06	3.59e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GGT1—liver cancer	5.33e-06	3.59e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GOT1—liver cancer	5.33e-06	3.59e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CRABP1—liver cancer	5.33e-06	3.58e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1B—liver cancer	5.31e-06	3.57e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GOT1—liver cancer	5.29e-06	3.55e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GGT1—liver cancer	5.29e-06	3.55e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GOT2—liver cancer	5.24e-06	3.52e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—liver cancer	5.21e-06	3.5e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—liver cancer	5.2e-06	3.5e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—liver cancer	5.2e-06	3.49e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—liver cancer	5.11e-06	3.44e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP1A1—liver cancer	5.08e-06	3.42e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—liver cancer	5.07e-06	3.4e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—liver cancer	5.03e-06	3.38e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CTNNB1—liver cancer	5.02e-06	3.37e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—liver cancer	4.94e-06	3.32e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2E1—liver cancer	4.92e-06	3.31e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—liver cancer	4.92e-06	3.31e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1A—liver cancer	4.9e-06	3.29e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—liver cancer	4.81e-06	3.23e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTP1—liver cancer	4.79e-06	3.22e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK8—liver cancer	4.78e-06	3.21e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.77e-06	3.2e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTP1—liver cancer	4.75e-06	3.19e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MTHFR—liver cancer	4.74e-06	3.19e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HMOX1—liver cancer	4.73e-06	3.18e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—liver cancer	4.72e-06	3.18e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CB—liver cancer	4.72e-06	3.18e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HMOX1—liver cancer	4.68e-06	3.15e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HPGDS—liver cancer	4.66e-06	3.13e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARA—liver cancer	4.65e-06	3.13e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—liver cancer	4.62e-06	3.1e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYCS—liver cancer	4.61e-06	3.1e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GGT1—liver cancer	4.52e-06	3.04e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GOT1—liver cancer	4.52e-06	3.04e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—liver cancer	4.47e-06	3e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—liver cancer	4.42e-06	2.97e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTM1—liver cancer	4.4e-06	2.96e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—liver cancer	4.37e-06	2.94e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTM1—liver cancer	4.37e-06	2.93e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—liver cancer	4.36e-06	2.93e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—liver cancer	4.27e-06	2.87e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.18e-06	2.81e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—liver cancer	4.18e-06	2.81e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1A1—liver cancer	4.17e-06	2.81e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PSMA4—liver cancer	4.15e-06	2.79e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PSMD10—liver cancer	4.15e-06	2.79e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1A1—liver cancer	4.14e-06	2.78e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—liver cancer	4.09e-06	2.75e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—liver cancer	4.06e-06	2.73e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTP1—liver cancer	4.06e-06	2.73e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFB1—liver cancer	4.05e-06	2.72e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GOT2—liver cancer	4.04e-06	2.72e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HMOX1—liver cancer	4e-06	2.69e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CG—liver cancer	3.98e-06	2.68e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MTHFR—liver cancer	3.89e-06	2.62e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MTHFR—liver cancer	3.86e-06	2.59e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARG—liver cancer	3.84e-06	2.58e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARA—liver cancer	3.82e-06	2.57e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2E1—liver cancer	3.8e-06	2.55e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARA—liver cancer	3.78e-06	2.54e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—liver cancer	3.77e-06	2.54e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—liver cancer	3.75e-06	2.52e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTM1—liver cancer	3.73e-06	2.51e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYCS—liver cancer	3.55e-06	2.39e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP1A1—liver cancer	3.54e-06	2.38e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CD—liver cancer	3.5e-06	2.35e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GGT1—liver cancer	3.49e-06	2.34e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GOT1—liver cancer	3.49e-06	2.34e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALB—liver cancer	3.46e-06	2.32e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—liver cancer	3.45e-06	2.32e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.4e-06	2.28e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—liver cancer	3.34e-06	2.24e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MTHFR—liver cancer	3.3e-06	2.22e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CG—liver cancer	3.27e-06	2.2e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CG—liver cancer	3.24e-06	2.18e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARA—liver cancer	3.23e-06	2.17e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—liver cancer	3.19e-06	2.15e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARG—liver cancer	3.16e-06	2.12e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTP1—liver cancer	3.13e-06	2.11e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARG—liver cancer	3.13e-06	2.1e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HMOX1—liver cancer	3.09e-06	2.08e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—liver cancer	3.05e-06	2.05e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CB—liver cancer	3.05e-06	2.05e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.91e-06	1.95e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—liver cancer	2.88e-06	1.94e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTM1—liver cancer	2.88e-06	1.93e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CD—liver cancer	2.87e-06	1.93e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CD—liver cancer	2.85e-06	1.92e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALB—liver cancer	2.84e-06	1.91e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—liver cancer	2.82e-06	1.89e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALB—liver cancer	2.81e-06	1.89e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CG—liver cancer	2.77e-06	1.86e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1A1—liver cancer	2.73e-06	1.83e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARG—liver cancer	2.67e-06	1.8e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTHFR—liver cancer	2.54e-06	1.71e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CB—liver cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARA—liver cancer	2.5e-06	1.68e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CB—liver cancer	2.48e-06	1.67e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CD—liver cancer	2.43e-06	1.64e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALB—liver cancer	2.4e-06	1.62e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—liver cancer	2.35e-06	1.58e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CG—liver cancer	2.14e-06	1.44e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CB—liver cancer	2.12e-06	1.43e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARG—liver cancer	2.06e-06	1.39e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CD—liver cancer	1.88e-06	1.26e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—liver cancer	1.86e-06	1.25e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALB—liver cancer	1.86e-06	1.25e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CB—liver cancer	1.64e-06	1.1e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—liver cancer	1.53e-06	1.03e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—liver cancer	1.52e-06	1.02e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—liver cancer	1.51e-06	1.02e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—liver cancer	1.29e-06	8.7e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—liver cancer	1.25e-06	8.38e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—liver cancer	1.24e-06	8.31e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—liver cancer	1.06e-06	7.1e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—liver cancer	9.99e-07	6.71e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—liver cancer	8.16e-07	5.48e-06	CbGpPWpGaD
